Recently, compelling evidence indicates that AURKA can act as a novel and promising antineoplastic target; its selective inhibitor, ALS, is a small molecule which has demonstrated the potent anticancer effect in the treatment of various types of cancer in preclinical and clinical studies [15,16,17,19,20,21,22,37]. Here, SOD1 is linked to cancer.